BE2014C053I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C053I2
BE2014C053I2 BE2014C053C BE2014C053C BE2014C053I2 BE 2014C053 I2 BE2014C053 I2 BE 2014C053I2 BE 2014C053 C BE2014C053 C BE 2014C053C BE 2014C053 C BE2014C053 C BE 2014C053C BE 2014C053 I2 BE2014C053 I2 BE 2014C053I2
Authority
BE
Belgium
Application number
BE2014C053C
Other languages
French (fr)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BE2014C053I2 publication Critical patent/BE2014C053I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BE2014C053C 2002-10-11 2014-09-09 BE2014C053I2 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002298259 2002-10-11
PCT/JP2003/013070 WO2004033463A1 (ja) 2002-10-11 2003-10-10 ２，３−ジヒドロ−６−ニトロイミダゾ[２，１−ｂ]オキサゾール化合物

Publications (1)

Publication Number Publication Date
BE2014C053I2 true BE2014C053I2 (zh) 2022-08-30

Family

ID=32089299

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C053C BE2014C053I2 (zh) 2002-10-11 2014-09-09

Country Status (27)

Country Link
US (1) US7262212B2 (zh)
EP (2) EP1555267B1 (zh)
JP (1) JP4186065B2 (zh)
KR (1) KR100723847B1 (zh)
CN (4) CN101255170A (zh)
AR (4) AR041198A1 (zh)
AU (1) AU2003272979B2 (zh)
BE (1) BE2014C053I2 (zh)
BR (1) BRPI0314344B8 (zh)
CA (1) CA2497569C (zh)
CY (2) CY1113578T1 (zh)
DK (1) DK1555267T3 (zh)
ES (1) ES2400179T3 (zh)
FR (1) FR14C0066I2 (zh)
HK (2) HK1085463A1 (zh)
HU (1) HUS1400046I1 (zh)
LU (1) LU92517I2 (zh)
MX (1) MXPA05003674A (zh)
MY (1) MY139244A (zh)
PL (3) PL409525A1 (zh)
PT (1) PT1555267E (zh)
RU (1) RU2326121C3 (zh)
SI (1) SI1555267T1 (zh)
TW (1) TWI347946B (zh)
UA (1) UA83200C2 (zh)
WO (1) WO2004033463A1 (zh)
ZA (1) ZA200501033B (zh)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
AR041605A1 (es) 2002-10-15 2005-05-26 Otsuka Pharma Co Ltd Compuesto 1- sustituido-4-nitroimidazol y metodo para preparar el mismo
ES2314460T3 (es) * 2003-10-31 2009-03-16 Otsuka Pharmaceutical Co., Ltd. Compuestos de 2,3-dihidro-6-nitroimidazo (2,1-b)oxazol para el tratamiento de la tuberculosis.
JP4761756B2 (ja) * 2003-10-31 2011-08-31 大塚製薬株式会社 ２，３−ジヒドロイミダゾ［２，１−ｂ］オキサゾ−ル化合物
TWI300409B (en) 2004-02-18 2008-09-01 Otsuka Pharma Co Ltd Method for producing 4-nitroimidazole compound
EP2650290A1 (en) 2004-03-31 2013-10-16 Nippon Soda Co., Ltd. Cyclic amine compound and pest control agent
JP4787529B2 (ja) * 2004-04-09 2011-10-05 大塚製薬株式会社 医薬組成物
JP4789966B2 (ja) * 2004-04-09 2011-10-12 大塚製薬株式会社 医薬組成物
US7408066B2 (en) * 2005-06-20 2008-08-05 Schering Corproation Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
MX2008001210A (es) * 2005-07-28 2008-03-24 Otsuka Pharma Co Ltd Composicion farmaceutica que comprende derivados de 2,3-dihidro-6-nitroimidazo{2,1-b]oxazol.
TW201434467A (zh) * 2005-10-05 2014-09-16 Otsuka Pharma Co Ltd 抗結核治療藥物及含彼之套組
JP5105818B2 (ja) * 2005-10-05 2012-12-26 大塚製薬株式会社 医薬組成物
EA014057B1 (ru) * 2005-10-06 2010-08-30 Ниппон Сода Ко., Лтд. Поперечно связанные соединения циклических аминов и средства для борьбы с вредителями
TW200800268A (en) * 2005-11-04 2008-01-01 Otsuka Pharma Co Ltd Medicinal composition showing improved drug absorbability
EP1968961A2 (en) 2005-12-21 2008-09-17 Decode Genetics EHF Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
US20090018169A1 (en) * 2006-02-13 2009-01-15 Laboratoires Serono Sa Sulfonamide Derivatives for the Treatment of Bacterial Infections
JP2007297305A (ja) * 2006-04-28 2007-11-15 Daiso Co Ltd Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法
JP5486928B2 (ja) * 2007-02-26 2014-05-07 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックウレアおよびカルバメートインヒビター
AR070301A1 (es) * 2007-05-08 2010-03-31 Otsuka Pharma Co Ltd Compuesto epoxi y metodo para producir el mismo
JP5451611B2 (ja) * 2007-07-26 2014-03-26 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター
US20110281909A1 (en) * 2007-08-15 2011-11-17 Glaxo Group Limited Substituted quinoline derivatives as h1 receptor antagonists
WO2009050204A1 (en) * 2007-10-16 2009-04-23 Glaxo Group Limited Quinoline derivatives used to treat inflammatory and allergic diseases
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
JP5490020B2 (ja) 2008-01-24 2014-05-14 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状カルバゼート及びセミカルバジドインヒビター
JP5734666B2 (ja) * 2008-02-11 2015-06-17 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の１，３−オキサアゼパン−２−オン及び１，３−ジアゼパン−２−オン阻害剤
US8598160B2 (en) * 2008-02-15 2013-12-03 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
US20110105504A1 (en) * 2008-03-18 2011-05-05 Vitae Pharmaceuticals ,Inc. Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1
CN101965353B (zh) * 2008-03-26 2014-12-17 丹诺医药(苏州）有限公司 共价连接到取代苯基噁唑烷酮的双环硝基咪唑类
US8242111B2 (en) * 2008-05-01 2012-08-14 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
JP5538365B2 (ja) 2008-05-01 2014-07-02 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
PL2300461T3 (pl) * 2008-05-01 2013-09-30 Vitae Pharmaceuticals Inc Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1
CL2009001058A1 (es) 2008-05-01 2010-09-10 Vitae Pharmaceuticals Inc Compuestos derivados de oxazinas sustituidas, inhibidores de la 11b-hidroxiesteroide deshidrogenasa de tipo-1; composicion farmaceutica; y uso del compuesto para inhibir la actividad de 11b-hsd1, como en el tratamiento de la diabetes, dislipidemia, hipertension, obesidad, cancer, glaucoma, entre otras.
EP2687525B1 (en) 2008-07-25 2015-09-23 Boehringer Ingelheim International GmbH Cyclic inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US20120040974A1 (en) * 2008-08-18 2012-02-16 Yale University Mif modulators
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
CN102131787B (zh) * 2008-08-21 2014-12-03 诺贝尔炸药及系统技术有限责任公司 制备2-卤代-4-硝基咪唑及其中间体的方法
WO2010143007A1 (en) * 2009-06-10 2010-12-16 Dynamit Nobel Gmbh Explosivstoff-Und Systemtechnik Method for the production of 2-halogeno-4-nitroimidazole
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
UA109255C2 (ru) 2009-04-30 2015-08-10 Берінгер Інгельхайм Інтернешнл Гмбх Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1
GEP20156309B (en) * 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
EP2448928B1 (en) 2009-07-01 2014-08-13 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
RU2540860C2 (ru) * 2009-07-31 2015-02-10 Глоубал Элаенс Фор Тб Драг Дивелопмент Нитроимидазооксазиновые и нитроимидазооксазольные аналоги и их применение
AU2010278777B2 (en) * 2009-07-31 2015-05-07 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
US9198913B2 (en) 2009-07-31 2015-12-01 Global Alliance For Tb Drug Development Nitroimidazooxazines and their uses in anti-tubercular therapy
JP5770096B2 (ja) 2009-10-26 2015-08-26 富士フイルムＲｉファーマ株式会社 感染症診断薬
TW201200523A (en) 2010-01-29 2012-01-01 Otsuka Pharma Co Ltd Synthetic intermediate of oxazole compound and method for producing the same
GB201012209D0 (en) * 2010-05-31 2010-09-08 Ge Healthcare Ltd In vivo imaging agent
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
WO2012059416A1 (en) 2010-11-02 2012-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical combinations for the treatment of metabolic disorders
US9051333B2 (en) 2011-04-15 2015-06-09 Otsuka Pharmaceutical Co., Ltd. 6,7-dihydroimidazo [2,1-b] [1,3]oxazine bactericides
JP2015006994A (ja) * 2011-10-28 2015-01-15 大正製薬株式会社 ジヒドロイミダゾオキサゾール誘導体
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
FR3000064A1 (fr) * 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes de type spiroisoxazoline ayant une activite potentialisatrice de l'activite d'un antibiotique-composition et produit pharmaceutiques comprenant de tels composes
IN2013DE02954A (zh) 2013-10-04 2015-04-10 Council Scient Ind Res
CN103524492A (zh) * 2013-10-23 2014-01-22 中国药科大学 侧链含硝基咪唑基团取代的喹诺酮类化合物、其制备及用途
AR101704A1 (es) 2014-08-28 2017-01-04 Otsuka Pharma Co Ltd Compuestos heterocíclicos fusionados
US9822126B1 (en) 2014-10-21 2017-11-21 Council Of Scientific & Industrial Research Substituted 1,2,3-triazol-1-yl-methyl-2,3-dihydro-2-methyl-6-nitroimidazo[2,1-b]oxazoles as anti-mycobacterial agents and a process for the preparation thereof
CN105732659B (zh) * 2014-12-12 2019-07-16 上海阳帆医药科技有限公司 硝基咪唑类化合物及其制备方法和在制药中的用途
US10227362B2 (en) 2015-01-29 2019-03-12 Medshine Discovery Inc. Anti-pulmonary tuberculosis nitroimidazole derivative
CN107406386B (zh) * 2015-03-27 2021-06-01 大塚制药株式会社 用于生产1-(4-羟基苯基)-4-(4-三氟甲氧基苯氧基)哌啶或其盐的方法
CN106317072B (zh) * 2015-06-17 2020-03-17 盟科医药技术(上海)有限公司 用于分枝杆菌感染治疗的杂环化合物及其应用
CN108884044B (zh) 2016-02-26 2023-01-31 大塚制药株式会社 哌啶衍生物
CN105859628B (zh) * 2016-04-19 2018-08-07 清远职业技术学院 一种抗菌化合物对n咪唑苯甲醛缩邻甲苯胺希夫碱及其制备方法和应用
MX2019000858A (es) * 2016-07-22 2019-11-11 Medshine Discovery Inc Cristal y sal de nitroimidazol y metodo de fabricacion de los mismos.
KR102657360B1 (ko) 2017-08-16 2024-04-16 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 신규 화합물
WO2019240104A1 (ja) 2018-06-11 2019-12-19 大塚製薬株式会社 デラマニド含有組成物
CN109705022A (zh) * 2018-12-28 2019-05-03 上海彩迩文生化科技有限公司 一种芳香胺中间体的制备方法
CN112300192B (zh) * 2019-08-02 2023-08-11 南京长澳医药科技有限公司 硝基咪唑类化合物及其制备方法和用途
CN110483549B (zh) * 2019-08-30 2021-03-05 沈阳药科大学 一种硝基咪唑吡喃类抗结核药物的制备方法
CN110615800A (zh) * 2019-10-16 2019-12-27 李丽丽 硝基咪唑类化合物及其制备方法和用途
CN112156088B (zh) * 2020-10-30 2021-08-31 健民药业集团股份有限公司 一种化合物在制备结核分枝杆菌抑制剂中的用途
CN113603706A (zh) * 2021-08-04 2021-11-05 深圳市泰力生物医药有限公司 德拉马尼的晶型、含有该晶型的活性药物和药物组合物
CN115368252B (zh) * 2022-09-19 2024-01-12 西北农林科技大学 一种4-胺基酚类衍生物及应用
CN116640106B (zh) * 2023-05-11 2024-03-08 郑州大学 一种苯基哌嗪类化合物及其制备方法、应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668127A (en) 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof

Also Published As

Publication number Publication date
PT1555267E (pt) 2013-01-29
CN101172981A (zh) 2008-05-07
AR086485A2 (es) 2013-12-18
EP1555267B1 (en) 2013-01-16
CA2497569A1 (en) 2004-04-22
ES2400179T3 (es) 2013-04-08
CN102532162B (zh) 2015-05-27
RU2005114017A (ru) 2006-01-20
HUS1400046I1 (hu) 2017-04-28
EP2570418A3 (en) 2013-07-03
CY1113578T1 (el) 2016-06-22
EP2570418A2 (en) 2013-03-20
AR041198A1 (es) 2005-05-04
AU2003272979A1 (en) 2004-05-04
LU92517I2 (fr) 2014-10-13
JP2004149527A (ja) 2004-05-27
BR0314344A (pt) 2005-07-12
WO2004033463A1 (ja) 2004-04-22
AU2003272979B2 (en) 2009-07-23
PL376157A1 (en) 2005-12-27
PL217919B1 (pl) 2014-09-30
TWI347946B (en) 2011-09-01
EP1555267A4 (en) 2010-08-18
CY2014041I2 (el) 2016-07-27
CN101255170A (zh) 2008-09-03
BRPI0314344B1 (pt) 2019-11-26
CN100366624C (zh) 2008-02-06
ZA200501033B (en) 2006-06-28
JP4186065B2 (ja) 2008-11-26
CY2014041I1 (el) 2016-07-27
EP1555267A1 (en) 2005-07-20
KR20050061473A (ko) 2005-06-22
DK1555267T3 (da) 2013-02-11
US20060094767A1 (en) 2006-05-04
CN102532162A (zh) 2012-07-04
PL409525A1 (pl) 2014-11-10
KR100723847B1 (ko) 2007-05-31
RU2326121C2 (ru) 2008-06-10
MXPA05003674A (es) 2005-06-08
US7262212B2 (en) 2007-08-28
HK1085463A1 (en) 2006-08-25
CA2497569C (en) 2011-05-24
UA83200C2 (en) 2008-06-25
FR14C0066I1 (zh) 2014-10-17
MY139244A (en) 2009-09-30
HK1171018A1 (zh) 2013-03-15
RU2326121C3 (ru) 2021-09-17
TW200420568A (en) 2004-10-16
PL404913A1 (pl) 2013-09-30
BRPI0314344B8 (pt) 2021-05-25
CN1705670A (zh) 2005-12-07
AR089950A2 (es) 2014-10-01
SI1555267T1 (sl) 2013-05-31
AR091771A2 (es) 2015-02-25
FR14C0066I2 (fr) 2015-05-22

Similar Documents

Publication Publication Date Title
BE2017C049I2 (zh)
BE2017C005I2 (zh)
BE2016C069I2 (zh)
BE2016C040I2 (zh)
BE2016C013I2 (zh)
BE2018C018I2 (zh)
BE2016C002I2 (zh)
BE2015C078I2 (zh)
BE2015C017I2 (zh)
FR14C0066I1 (zh)
BE2014C051I2 (zh)
BE2014C041I2 (zh)
BE2014C030I2 (zh)
BE2014C016I2 (zh)
BE2014C015I2 (zh)
BE2013C063I2 (zh)
BE2013C039I2 (zh)
BE2015C068I2 (zh)
BE2011C038I2 (zh)
JP2003177869A5 (zh)
BE2013C046I2 (zh)
JP2003205916A5 (zh)
JP2003248350A5 (zh)
JP2003205099A5 (zh)
JP2003094179A5 (zh)